Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (8): 825-833.doi: 10.3969/j.issn.1000-6621.2018.08.010
• Original Articles • Previous Articles Next Articles
Qing WANG,Dong-chun MA,Jie LIU,Song YAO,Xiao-hong KAN,Fang-jin BAO,Ai-min WANG,Si-jiu SHI,Xiao-min XU,Xue-hui FANG,Gen-you ZHANG,Yun-sheng DING,Xun-di BAO()
Received:
2018-02-24
Online:
2018-08-10
Published:
2018-09-09
Contact:
Xun-di BAO
E-mail:baoxundi@163.com
Qing WANG,Dong-chun MA,Jie LIU,Song YAO,Xiao-hong KAN,Fang-jin BAO,Ai-min WANG,Si-jiu SHI,Xiao-min XU,Xue-hui FANG,Gen-you ZHANG,Yun-sheng DING,Xun-di BAO. Analysis of drug resistance baseline in smear positive pulmonary tuberculosis patients in Anhui province[J]. Chinese Journal of Antituberculosis, 2018, 40(8): 825-833. doi: 10.3969/j.issn.1000-6621.2018.08.010
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.08.010
社会人口学特征 | 合计(2530例) | 初治涂阳(2133例) | 复治涂阳(397例) | χ2值 | P值 |
---|---|---|---|---|---|
性别 | 9.64 | 0.002 | |||
男 | 1958(77.39) | 1627(76.28) | 331(83.38) | ||
女 | 572(22.61) | 506(23.72) | 66(16.62) | ||
年龄(岁) | 48.59 | 0.000 | |||
0~ | 76(3.00) | 76(3.56) | 0(0.00) | ||
20~ | 612(24.19) | 556(26.07) | 56(14.11) | ||
40~ | 727(28.74) | 578(27.10) | 149(37.53) | ||
60~ | 1115(44.07) | 923(43.27) | 192(48.36) | ||
地区 | 0.08 | 0.962 | |||
皖北 | 1061(41.94) | 892(41.82) | 169(42.57) | ||
皖中 | 1083(42.80) | 915(42.90) | 168(42.32) | ||
皖南 | 386(15.26) | 326(15.28) | 60(15.11) | ||
职业 | 28.13 | 0.000 | |||
农民 | 1869(73.87) | 1554(72.85) | 315(79.34) | ||
企业职工 | 103(4.07) | 94(4.41) | 9(2.27) | ||
离退休 | 120(4.74) | 90(4.22) | 30(7.56) | ||
待岗 | 149(5.89) | 133(6.23) | 16(4.03) | ||
学生 | 70(2.77) | 68(3.19) | 2(0.50) | ||
医生 | 12(0.48) | 11(0.52) | 1(0.25) | ||
其他 | 207(8.18) | 183(8.58) | 24(6.05) | ||
文化程度 | 19.88 | 0.001 | |||
文盲 | 712(28.14) | 602(28.22) | 110(27.71) | ||
小学 | 639(25.26) | 514(24.10) | 125(31.49) | ||
初中 | 727(28.74) | 611(28.65) | 116(29.22) | ||
高中 | 290(11.46) | 255(11.95) | 35(8.81) | ||
大专及以上 | 162(6.40) | 151(7.08) | 11(2.77) | ||
家庭年收入(万元) | 3.37 | 0.338 | |||
<2 | 1423(56.25) | 1188(55.70) | 235(59.19) | ||
2~ | 690(27.27) | 582(27.28) | 108(27.21) | ||
>5 | 231(9.13) | 203(9.52) | 28(7.05) | ||
拒绝透露 | 186(7.35) | 160(7.50) | 26(6.55) |
抗结核 药物 | 合计(2530株) | 初治涂阳(2133株) | 复治涂阳(397株) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
耐药株数 | 耐药率(%) | 耐药株数 | 耐药率(%) | 耐药株数 | 耐药率(%) | |||
INH | 337 | 13.32 | 223 | 10.45 | 114 | 28.72 | 96.66 | 0.000 |
RFP | 289 | 11.42 | 163 | 7.64 | 126 | 31.74 | 192.07 | 0.000 |
Sm | 321 | 12.69 | 234 | 10.97 | 87 | 21.91 | 36.19 | 0.000 |
EMB | 74 | 2.92 | 40 | 1.88 | 34 | 8.56 | 52.74 | 0.000 |
Ofx | 225 | 8.89 | 139 | 6.52 | 86 | 21.66 | 94.76 | 0.000 |
Km | 41 | 1.62 | 30 | 1.41 | 11 | 2.77 | 3.10 | 0.078 |
合计 | 669 | 26.44 | 478 | 22.41 | 191 | 48.11 | 113.67 | 0.000 |
一般特征 | 合计 | 初治涂阳 | 复治涂阳 | χ2值 | P值 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
菌株 数 | 耐药 株数 | 耐药率 (%) | 菌株 数 | 耐药 株数 | 耐药率 (%) | 菌株 数 | 耐药 株数 | 耐药率 (%) | |||
性别 | 0.31 | 0.580 | |||||||||
男 | 1958 | 524 | 26.76 | 1627 | 368 | 22.62 | 331 | 156 | 47.13 | ||
女 | 572 | 145 | 25.35 | 506 | 110 | 21.74 | 66 | 35 | 53.03 | ||
年龄(岁) | 7.65 | 0.054 | |||||||||
0~ | 76 | 24 | 31.58 | 76 | 24 | 31.58 | 0 | 0 | 0.00 | ||
20~ | 612 | 147 | 24.02 | 556 | 115 | 20.68 | 56 | 32 | 57.14 | ||
40~ | 727 | 216 | 29.71 | 578 | 134 | 23.18 | 149 | 82 | 55.03 | ||
60~ | 1115 | 282 | 25.29 | 923 | 205 | 22.21 | 192 | 77 | 40.10 | ||
地区 | 0.37 | 0.831 | |||||||||
皖北 | 1061 | 287 | 27.05 | 892 | 212 | 23.77 | 169 | 75 | 44.38 | ||
皖中 | 1083 | 282 | 26.04 | 915 | 193 | 21.09 | 168 | 89 | 52.98 | ||
皖南 | 386 | 100 | 25.91 | 326 | 73 | 22.39 | 60 | 27 | 45.00 | ||
合计 | 2530 | 669 | 26.44 | 2133 | 478 | 22.41 | 397 | 191 | 48.11 | 113.67 | 0.000 |
耐药谱 | 合计(2530株) | 初治涂阳(2133株) | 复治涂阳(397株) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
耐多药 株数 | 耐多药 率(%) | 耐多药 株数 | 耐多药 率(%) | 耐多药 株数 | 耐多药 率(%) | |||
INH+RFP+Sm | 112 | 58.03 | 64 | 60.38 | 48 | 55.17 | 0.53 | 0.466 |
INH+RFP+EMB | 61 | 31.61 | 32 | 30.19 | 29 | 33.33 | 0.22 | 0.640 |
INH+RFP+Ofx | 83 | 43.01 | 40 | 37.74 | 43 | 49.43 | 2.66 | 0.103 |
INH+RFP+Km | 23 | 11.92 | 13 | 12.26 | 10 | 11.49 | 0.03 | 0.870 |
INH+RFP+Sm+EMB | 38 | 19.69 | 20 | 18.87 | 18 | 20.69 | 0.10 | 0.751 |
INH+RFP+Sm+Ofx | 52 | 26.94 | 26 | 24.53 | 26 | 29.89 | 0.70 | 0.404 |
INH+RFP+Sm+Km | 15 | 7.77 | 10 | 9.43 | 5 | 5.75 | 0.91 | 0.341 |
INH+RFP+EMB+Ofx | 39 | 20.21 | 18 | 16.98 | 21 | 24.14 | 1.52 | 0.218 |
INH+RFP+EMB+Km | 14 | 7.25 | 9 | 8.49 | 5 | 5.75 | 0.54 | 0.465 |
INH+RFP+Ofx+Sm | 23 | 11.92 | 13 | 12.26 | 10 | 11.49 | 0.03 | 0.870 |
INH+RFP+Sm+EMB+Ofx | 29 | 15.03 | 14 | 13.21 | 15 | 17.24 | 0.61 | 0.435 |
INH+RFP+Sm+EMB+Km | 11 | 5.70 | 8 | 7.55 | 3 | 3.45 | 0.83 | 0.363 |
INH+RFP+EMB+Ofx+Km | 14 | 7.25 | 9 | 8.49 | 5 | 5.75 | 0.54 | 0.465 |
INH+RFP+Sm+EMB+Ofx+Km | 11 | 5.70 | 8 | 7.55 | 3 | 3.45 | 0.83 | 0.363 |
合计 | 193 | 7.63 | 106 | 4.97 | 87 | 21.91 | 3.74 | 0.053 |
一般特征 | 合计 | 初治涂阳 | 复治涂阳 | χ2值 | P值 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
菌株 数 | 耐多药 株数 | 耐多药 率(%) | 菌株 数 | 耐多药 株数 | 耐多药 率(%) | 菌株 数 | 耐多药 株数 | 耐多药 率(%) | |||
性别 | 0.61 | 0.434 | |||||||||
男 | 1958 | 145 | 7.41 | 1627 | 78 | 4.79 | 331 | 67 | 20.24 | ||
女 | 572 | 48 | 8.39 | 506 | 28 | 5.53 | 66 | 20 | 30.30 | ||
年龄(岁) | 16.72 | 0.001 | |||||||||
0~ | 76 | 7 | 9.21 | 76 | 7 | 9.21 | 0 | 0 | 0.00 | ||
20~ | 612 | 42 | 23.86 | 556 | 27 | 4.86 | 56 | 15 | 26.79 | ||
40~ | 727 | 79 | 29.71 | 578 | 36 | 6.23 | 149 | 43 | 28.86 | ||
60~ | 1115 | 65 | 25.02 | 923 | 36 | 3.90 | 192 | 29 | 15.10 | ||
地区 | 7.33 | 0.026 | |||||||||
皖北 | 1061 | 96 | 9.05 | 892 | 60 | 6.73 | 169 | 36 | 21.30 | ||
皖中 | 1083 | 78 | 7.20 | 915 | 35 | 3.83 | 168 | 43 | 25.60 | ||
皖南 | 386 | 19 | 4.92 | 326 | 11 | 3.37 | 60 | 8 | 13.33 | ||
合计 | 2530 | 193 | 7.63 | 2133 | 106 | 4.97 | 397 | 87 | 21.91 | 3.74 | 0.053 |
多耐药类型 耐药谱 | 合计(2530株) | 初治(2133株) | 复治(397株) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
多耐药 株数 | 多耐药 率(%) | 多耐药 株数 | 多耐药 率(%) | 多耐药 株数 | 多耐药 率(%) | |||
耐2种药 | 314 | 12.41 | 191 | 8.95 | 123 | 30.98 | 149.40 | 0.000 |
INH+EMB | 65 | 2.57 | 35 | 1.64 | 30 | 7.56 | 46.80 | 0.000 |
INH+Sm | 173 | 6.84 | 116 | 5.44 | 57 | 14.36 | 41.80 | 0.000 |
INH+Ofx | 98 | 3.87 | 47 | 2.20 | 51 | 12.85 | 101.82 | 0.000 |
INH+Km | 28 | 1.11 | 18 | 0.84 | 10 | 2.52 | 8.58 | 0.003 |
RFP+EMB | 67 | 2.65 | 34 | 1.59 | 33 | 8.31 | 58.60 | 0.000 |
RFP+Sm | 141 | 5.57 | 76 | 3.56 | 65 | 16.37 | 104.36 | 0.000 |
RFP+Ofx | 100 | 3.95 | 48 | 2.25 | 52 | 13.10 | 103.75 | 0.000 |
RFP+Km | 26 | 1.03 | 15 | 0.70 | 11 | 2.77 | 14.07 | 0.000 |
EMB+Sm | 45 | 1.78 | 25 | 1.17 | 20 | 5.04 | 28.63 | 0.000 |
EMB+Ofx | 43 | 1.70 | 20 | 0.94 | 23 | 5.79 | 46.91 | 0.000 |
EMB+Km | 14 | 0.55 | 9 | 0.42 | 5 | 1.26 | 2.88 | 0.090 |
Sm+Ofx | 78 | 3.08 | 41 | 1.92 | 37 | 9.32 | 61.05 | 0.000 |
Sm+Km | 21 | 0.83 | 15 | 0.70 | 6 | 1.51 | 1.76 | 0.184 |
Ofx+Km | 26 | 1.03 | 15 | 0.70 | 11 | 2.77 | 12.11 | 0.001 |
耐3种药 | 181 | 7.15 | 99 | 4.64 | 82 | 20.65 | 129.22 | 0.000 |
INH+Sm+EMB | 41 | 1.62 | 23 | 1.08 | 18 | 4.53 | 25.07 | 0.000 |
INH+Sm+Ofx | 58 | 2.29 | 30 | 1.41 | 28 | 7.05 | 47.64 | 0.000 |
INH+Sm+Km | 19 | 0.75 | 14 | 0.66 | 5 | 1.26 | 0.92 | 0.336 |
INH+EMB+Ofx | 41 | 1.62 | 19 | 0.89 | 22 | 5.54 | 45.41 | 0.000 |
INH+EMB+Km | 14 | 0.55 | 9 | 0.42 | 5 | 1.26 | 2.88 | 0.090 |
INH+Ofx+Km | 23 | 0.91 | 13 | 0.61 | 10 | 2.52 | 11.51 | 0.001 |
RFP+Sm+EMB | 42 | 1.66 | 22 | 1.03 | 20 | 5.04 | 32.91 | 0.000 |
RFP+Sm+Ofx | 62 | 2.45 | 28 | 1.31 | 34 | 8.56 | 73.63 | 0.000 |
RFP+Sm+Km | 17 | 0.67 | 11 | 0.52 | 6 | 1.51 | 3.59 | 0.058 |
RFP+Ofx+Km | 25 | 0.99 | 14 | 0.66 | 11 | 2.77 | 13.21 | 0.000 |
Sm+EMB+Ofx | 32 | 1.26 | 16 | 0.75 | 16 | 4.03 | 28.84 | 0.000 |
Sm+EMB+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
Sm+Ofx+Km | 17 | 0.67 | 11 | 0.52 | 6 | 1.51 | 3.55 | 0.058 |
EMB+Ofx+Km | 14 | 0.55 | 9 | 0.42 | 5 | 1.26 | 2.88 | 0.090 |
耐3种以上 | 77 | 3.04 | 39 | 1.83 | 38 | 9.57 | 68.01 | 0.000 |
INH+Sm+EMB+Ofx | 30 | 1.19 | 15 | 0.70 | 15 | 3.78 | 24.45 | 0.000 |
INH+Sm+EMB+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
INH+Sm+Ofx+Km | 15 | 0.59 | 10 | 0.47 | 5 | 1.26 | 2.34 | 0.126 |
INH+EMB+Ofx+Km | 14 | 0.55 | 9 | 0.42 | 5 | 1.26 | 2.88 | 0.090 |
RFP+Sm+EMB+Ofx | 31 | 1.23 | 15 | 0.70 | 16 | 4.03 | 27.92 | 0.000 |
RFP+Sm+EMB+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
RFP+EMB+Ofx+Km | 18 | 0.71 | 9 | 0.42 | 9 | 2.27 | 13.62 | 0.000 |
RFP+Sm+Ofx+Km | 17 | 0.67 | 11 | 0.52 | 6 | 1.51 | 3.59 | 0.058 |
Sm+EMB+Ofx+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
INH+Sm+EMB+Ofx+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
RFP+Sm+EMB+Ofx+Km | 11 | 0.43 | 8 | 0.38 | 3 | 0.76 | 0.41 | 0.520 |
合计 | 314 | 12.41 | 191 | 8.95 | 123 | 30.98 | 149.40 | 0.000 |
一般特征 | 合计 | 初治涂阳 | 复治涂阳 | χ2值 | P值 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
菌株 数 | 多耐药 株数 | 多耐药 率(%) | 菌株 数 | 多耐药 株数 | 多耐药 率(%) | 菌株 数 | 多耐药 株数 | 多耐药 率(%) | |||
性别 | 0.19 | 0.664 | |||||||||
男 | 1958 | 240 | 12.26 | 1627 | 144 | 8.85 | 331 | 96 | 29.00 | ||
女 | 572 | 74 | 12.94 | 506 | 47 | 9.29 | 66 | 27 | 40.91 | ||
年龄组(岁) | 9.87 | 0.020 | |||||||||
0~ | 76 | 11 | 14.47 | 76 | 11 | 14.47 | 0 | 0 | 0.00 | ||
20~ | 612 | 70 | 11.44 | 556 | 48 | 8.63 | 56 | 22 | 39.29 | ||
40~ | 727 | 113 | 15.54 | 578 | 56 | 9.69 | 149 | 57 | 38.26 | ||
60~ | 1115 | 120 | 10.76 | 923 | 76 | 8.23 | 192 | 44 | 22.92 | ||
地区 | 1.76 | 0.415 | |||||||||
皖北 | 1061 | 136 | 12.82 | 892 | 89 | 9.98 | 169 | 47 | 27.81 | ||
皖中 | 1083 | 138 | 12.74 | 915 | 79 | 8.63 | 168 | 59 | 35.12 | ||
皖南 | 386 | 40 | 10.36 | 326 | 23 | 7.06 | 60 | 17 | 28.33 | ||
合计 | 2530 | 314 | 12.41 | 2133 | 191 | 8.95 | 397 | 123 | 30.98 | 149.40 | 0.000 |
一般特征 | 合计(2530株) | 初治涂阳(2133株) | 复治涂阳(397株) | χ2值 | P值 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
菌株 数 | 广泛耐药 株数 | 广泛耐药 率(%) | 菌株 数 | 广泛耐药 株数 | 广泛耐药 率(%) | 菌株 数 | 广泛耐药 株数 | 广泛耐药 率(%) | |||
性别 | 0.16 | 0.689 | |||||||||
男 | 1958 | 17 | 0.87 | 1627 | 10 | 0.61 | 831 | 7 | 0.84 | ||
女 | 572 | 6 | 1.05 | 506 | 3 | 0.59 | 66 | 3 | 4.55 | ||
年龄(岁) | 8.29 | 0.016 | |||||||||
0~ | 76 | 0 | 0.00 | 76 | 0 | 0.00 | 0 | 0 | 0.00 | ||
20~ | 612 | 7 | 1.14 | 556 | 4 | 0.72 | 56 | 3 | 5.36 | ||
40~ | 727 | 12 | 1.65 | 578 | 7 | 1.21 | 149 | 5 | 3.36 | ||
60~ | 1115 | 4 | 0.36 | 923 | 2 | 0.22 | 192 | 2 | 1.04 | ||
地区 | 8.91 | 0.003 | |||||||||
皖北 | 1061 | 19 | 1.79 | 892 | 12 | 1.35 | 169 | 7 | 4.14 | ||
皖中 | 1083 | 4 | 0.37 | 915 | 1 | 0.11 | 168 | 3 | 1.79 | ||
皖南 | 386 | 0 | 0.00 | 326 | 0 | 0.00 | 60 | 0 | 0.00 | ||
合计 | 2530 | 23 | 0.91 | 2133 | 13 | 0.61 | 397 | 10 | 2.52 | 13.55 | 0.000 |
[1] | World Health Organization . Global tuberculosis report 2016. Geveva:World Health Organization, 2016. |
[2] | World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[3] | 杜敬华, 刘建春, 王爱民 , 等. 药物敏感性试验在耐药结核病治疗中的效果分析. 中国医药导刊, 2016,18(12):1274-1275,1277. |
[4] | World Health Organization . Guidelines for surveillance of drug resistance in tuberculosis,Fourth Edition. Geneva: World Health Organization, 2009. |
[5] | 中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年).北京: 人民卫生出版社, 2010. |
[6] | 中国防痨协会. 结核病诊断细菌学检验规程. 中国防痨杂志, 1996,18(1):28-31. |
[7] | 邹级谦 . 肺结核诊断标准. 结核病健康教育, 2008,1:7-9. |
[8] | 中华人民共和国卫生部.可感染人类的高致病性病原微生物菌(毒)种或样本运输管理规定. 中华人民共和国卫生部令第45号. 2005 -12-28. |
[9] |
Zhao Y, Xu S, Wang I , et al. National survey of drug-resistant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170.
doi: 10.1056/NEJMoa1108789 URL |
[10] |
徐东芳, 王庆, 李孳 , 等. 安徽省420株结核分枝杆菌对一线和二线抗结核药物药敏结果分析. 中国人兽共患病学报, 2014,30(1):54-57.
doi: 10.3969/cjz.j.issn.1002-2694.2014.01.012 URL |
[11] |
李亮, 杜建 . 修订版耐药结核病规划管理指南对中国耐药结核病防治工作的启示. 中华结核和呼吸杂志, 2010,33(7):498-499.
doi: 10.3760/cma.j.issn.1001-0939.2010.07.005 URL |
[12] | 陈聪, 张云侠, 姚芳 , 等. 耐多药肺结核的影响因素及风险预测. 公共卫生与预防医学, 2017,28(2):49-51. |
[13] |
张正冬, 张海燕, 林存智 . WHO第四版结核病治疗指南解读. 中华临床医师杂志(电子版), 2014,8(12):4251-4253.
doi: 10.3877/cma.j.issn.1674-0785.2014.23.020 URL |
[14] |
郑春秀, 崔振玲 . 耐药结核病流行状况调查分析. 检验医学与临床, 2014,11(9):1156-1158.
doi: 10.3969/j.issn.1672-9455.2014.09.002 URL |
[15] |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版). 中华结核和呼吸杂志, 2016,39(4):253-279.
doi: 10.3760/cma.j.issn.1001-0939.2016.04.001 URL |
[16] |
Yang C, Luo T, Shen X , et al. TranSmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a re-trospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284.
doi: 10.1016/S1473-3099(16)30418-2 URL |
[17] |
高谦, 梅建 . 传播才是造成我国结核病高耐药率的主要原因. 中国防痨杂志, 2015,37(11):1091-1096.
doi: 10.3969/j.issn.1000-6621.2015.11.002 URL |
[18] | 唐神结, 肖和平 . 严重耐多药结核病的研究进展. 中华结核和呼吸杂志, 2009,32(5):380-383. |
[19] |
阚晓宏, 万康林, 杨建安 , 等. 安徽省结核病结核杆菌耐药状况的调查. 安徽医学, 2009,30(5):507-509.
doi: 10.3969/j.issn.1000-0399.2009.05.004 URL |
[20] | 杜建, 徐彩红, 李琦 , 等. 不同类型治疗方案治疗耐多药结核病效果文献分析. 中国防痨杂志, 2010,32(8):421-426. |
[21] | 姜国义, 董国力 . 耐药结核病的管理与控制策略. 中国卫生产业, 2017,14(31):131-132. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||